Egle Therapeutics nabs $46M as it looks to push into the clinic with next-gen Tregs platform

After launching last year and swiftly grabbing a Takeda deal, European Treg biotech Egle Therapeutics has bulked up its coffers with a 40 million euro ($46.4 million) funding round.